Skip Navigation

JNCI Journal of the National Cancer Institute 2004 96(7):524-528; doi:10.1093/jnci/djh084
© 2004 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (27)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Jacobs, E. J.
Right arrow Articles by Thun, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jacobs, E. J.
Right arrow Articles by Thun, M. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 Oxford University Press

ARTICLE

Aspirin Use and Pancreatic Cancer Mortality in a Large United States Cohort

Eric J. Jacobs, Cari J. Connell, Carmen Rodriguez, Alpa V. Patel, Eugenia E. Calle, Michael J. Thun

Affiliation of authors: Department of Epidemiology and Surveillance Research, American Cancer Society, Atlanta, GA.

Correspondence to:Eric J. Jacobs, PhD, Department of Epidemiology and Surveillance Research, American Cancer Society, National Home Office, 1599 Clifton Rd. NE, Atlanta, GA 30329 (e-mail: eric.jacobs{at}cancer.org)

Background: Results from some epidemiologic studies have suggested that aspirin use may reduce risk of pancreatic cancer, but the evidence remains limited. Methods: We examined the association between aspirin use and pancreatic cancer mortality among 987 590 U.S. adults in the Cancer Prevention Study II (CPS-II) cohort. CPS-II participants completed a self-administered questionnaire in 1982 and were followed for mortality through 2000. During follow-up, there were 4577 deaths from pancreatic cancer (2434 in men and 2143 in women). We calculated rate ratios (RR) adjusted for age, sex, race, body mass index, diabetes, and cigarette smoking status. Results: Aspirin use was not associated with pancreatic cancer mortality. The rate ratio associated with aspirin use 30 or more times per month, compared with no use, was 0.97 (95% confidence interval [CI] = 0.86 to 1.09). Even participants who reported both frequent aspirin use (>=30 times per month) and use for 20 or more years were not at decreased risk compared with nonusers (RR = 0.96, 95% CI = 0.69 to 1.33). We found no association between aspirin use and pancreatic cancer mortality in subgroup analyses by follow-up time, cigarette smoking status, or sex. Conclusion: Results from this large prospective study do not support an important effect of aspirin use on pancreatic cancer mortality.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cancer Res.Home page
A. N. Viswanathan, D. Feskanich, E. S. Schernhammer, and S. E. Hankinson
Aspirin, NSAID, and Acetaminophen Use and the Risk of Endometrial Cancer
Cancer Res., April 1, 2008; 68(7): 2507 - 2513.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
S. C. Larsson, E. Giovannucci, L. Bergkvist, and A. Wolk
Aspirin and Nonsteroidal Anti-inflammatory Drug Use and Risk of Pancreatic Cancer: A Meta-analysis
Cancer Epidemiol. Biomarkers Prev., December 1, 2006; 15(12): 2561 - 2564.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. Jimeno, M. L. Amador, P. Kulesza, X. Wang, B. Rubio-Viqueira, X. Zhang, A. Chan, J. Wheelhouse, H. Kuramochi, K. Tanaka, et al.
Assessment of celecoxib pharmacodynamics in pancreatic cancer
Mol. Cancer Ther., December 1, 2006; 5(12): 3240 - 3247.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
M. Abdelrahim, C. H. Baker, J. L. Abbruzzese, and S. Safe
Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation.
J Natl Cancer Inst, June 21, 2006; 98(12): 855 - 868.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
A Juuti, J Louhimo, S Nordling, A Ristimaki, and C Haglund
Cyclooxygenase-2 expression correlates with poor prognosis in pancreatic cancer
J. Clin. Pathol., April 1, 2006; 59(4): 382 - 386.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.